Q32 Bio (QTTB) Research & Development (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Research & Development of $3.2 million for Q1 2026, down 54.83% year-over-year from $7.1 million in Q1 2025, and down 2.93% quarter-over-quarter from $3.3 million in Q4 2025.
Q32 Bio (QTTB) Research & Development (2017 - 2026) Analysis & Trends
Q32 Bio's Research & Development history runs 10 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Research & Development fell 54.83% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $15.2 million (down 66.43% YoY), while the FY2025 annual figure was $19.2 million, down 60.21% from the prior year.
- Research & Development for Q1 2026 stood at $3.2 million, down from $3.3 million in the prior quarter.
- The five-year high for Research & Development was $27.1 million in Q4 2022, with the low at $3.2 million in Q1 2026.
- The 5-year median for Research & Development is $8.3 million (2023), against an average of $11.8 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development soared 92.23% in 2024, then sank 75.22% in 2025.
- Q32 Bio's Research & Development stood at $27.1 million in 2022, then plunged by 69.28% to $8.3 million in 2023, then advanced by 26.45% to $10.5 million in 2024, then slumped by 68.56% to $3.3 million in 2025, then decreased by 2.93% to $3.2 million in 2026.
- Business Quant data shows QTTB's Research & Development at $3.2 million in Q1 2026, $3.3 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | 4.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.26 Mn |
| Mar 31, 2026 | 3.22 Mn |
| Dec 31, 2025 | 3.32 Mn |
| Sep 30, 2025 | 3.56 Mn |
| Jun 30, 2025 | 5.16 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | 10.55 Mn |
| Sep 30, 2024 | 14.35 Mn |
| Jun 30, 2024 | 13.41 Mn |
| Mar 31, 2024 | 9.84 Mn |
| Dec 31, 2023 | 8.34 Mn |
| Sep 30, 2023 | 7.46 Mn |
| Jun 30, 2023 | 8.02 Mn |
| Mar 31, 2023 | 7.91 Mn |
| Dec 31, 2022 | 27.15 Mn |
| Sep 30, 2022 | 25.85 Mn |
| Jun 30, 2022 | 21.08 Mn |
| Mar 31, 2022 | 24.27 Mn |
| Dec 31, 2021 | 23.65 Mn |
| Sep 30, 2021 | 23.99 Mn |